Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Breast Cancer

 

Premenopausal Early Assessment; ER+, HER2-, FLT (7536a)
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01928186

Vaccine Therapy for HER2+ Stage IV Breast Cancer
Phase II Study to Evaluate the Development of HER2/neu (HER2)-Specific Memory T Cells After HER2 Peptide-Based Vaccination in Patients with Advanced Stage HER2+ Breast Cancer

Investigator: Lupe Salazar, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01729884

Postmenopausal Early Assessment; ER+, HER2-, FLT (7536b)
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01928186

Pertuzumab in Combination With Herceptin and Vinorelbine for Metastatic or HER2-Positive Breast Cancer (UW12012)
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Temporarily On Hold;   Study ID: NCT01565083

Targeted Therapies for Triple Negative Advanced Breast Cancer (6628)
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel (Abraxane) and Bevacizumab (Avastin) Followed by Maintenance Targeted Therapy With Bevacizumab (Avastin) and Erlotinib (Tarceva)

Investigator: Jennifer Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT00733408

PARP Inhibitor ABT-888 with Cisplatin and Vinorelbine (7161)
Phase I Study of ABT-888 (Veliparib) in Combination With Cisplatin and Vinorelbine (Navelbine) for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer

Investigator: Eve Rodler, MD;   Conditions: Advanced Breast Cancer;    Status: Recruiting;   Study ID: NCT01104259

Depocyt-Methotrexate trial for Leptomeningeal Metastases (6954)
A Phase II Study of the Combination of High-dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients with Parenchymal and Leptomeningeal Metastases from Breast Cancer

Investigator: Maciej Mrugala, MD, PhD;   Conditions: Stage IV Breast Cancer, Central Nervous System Involvement/Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer, Tumors Metastatic to Brain;    Status: Open;   Study ID: NCT00992602

Ampligen w/Vaccine Therapy for Stage II-IV HER2-Positive Breast Cancer (7425)
Phase I-II Study of HER2 Vaccination with poly(I) poly(C12U) (AmpligenĀ®) as an Adjuvant in Optimally Treated Breast Cancer Patients

Investigator: Lupe Salazar, MD;   Conditions: Breast Cancer;    Status: Pending;   Study ID: NCT01355393

Monitoring Patients with Triple Negative Breast Cancer (8132)
Intensive Trial of OMics in Cancer (ITOMIC) 001- Intensive Longitudinal Monitoring in Patients with Triple Negative Breast Cancer

Investigator: Tony Blau, MD;   Conditions: Breast Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT01957514

Vorinostat + Hormone Therapy for Stage IV Breast Cancer (7841)
A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B

Investigator: Hannah Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01720602

I-SPY2 Trial (7518)
I-SPY2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis 2)

Investigator: Larissa Korde;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01042379

FES Imaging in Response to Hormone Therapy (6357)
A Phase 2 Study of [18F]fluoroestradiol (FES) Imaging and Response to Hormonal Therapy

Investigator: David Mankoff, M.D., PhD ;   Conditions: Breast Cancer;    Status: Recruiting

Vaccine Therapy and Trastuzumab w/wo Polysaccharide-K for Stage IV HER2 Positive Breast Cancer
Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSKĀ®) Concurrently With a HER2 ICD Peptide-Based Vaccine and Trastuzumab in Patients With Stage IV Breast Cancer

Investigator: Lupe G. Salazar, MD;   Conditions: HER2-positive Breast Cancer;    Status: Pending;   Study ID: NCT01922921

Psychoeducation for Spouses of Women With Breast Cancer
Psychoeducation for Spouses of Women With Breast Cancer (Helping Her Heal)

Investigator: ;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01723943

SPORE Project 3 (7587)
Quantitative Dynamic PET and MRI and Breast Cancer Therapy

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01931709

TDM1 Platelet (7900)
Thrombokinetic Studies of Trastuzumab Emtansine

Investigator: V.K. Gadi, MD, PhD;   Conditions: Breast Cancer;    Status: Pending;   Study ID: NCT01816035

Eribulin Mesylate for Previously Treated Metastatic Breast Cancer (8093)
Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01908101

PD-0332991 + Letrozole vs. Letrozole ER+/HER2- Advanced Breast Cancer (UW13012)
A Randomized, Multicenter, Double-Blind Phase 3 Study Of PD-0332991 (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With ER (+), HER2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment For Advanced Disease

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Neoplasms;    Status: Recruiting;   Study ID: NCT01740427